Quality of Life in CSU Shaped by More Than Skin Symptoms

A newly published narrative review highlights the substantial psychiatric burden associated with chronic spontaneous urticaria (CSU), underscoring the need for routine psychological assessment and multidisciplinary management in affected patients. The review, published in the Indian Dermatology Online Journal, synthesizes current evidence linking CSU with anxiety, depression, sleep disturbances, stress-related disorders, and reduced quality of life, while also examining emerging neuroimmune mechanisms that may help explain these associations.¹

MORE ON CSU

According to the authors, psychiatric comorbidities affect approximately one-third of patients with CSU, making them among the most common yet frequently overlooked aspects of disease management. Sleep-wake disorders were reported as the most prevalent psychiatric condition, affecting 36.7% of patients, followed by anxiety disorders (30.6%) and mood disorders (29.4%). Trauma- and stressor-related disorders, somatic symptom disorders, obsessive-compulsive disorders, and substance use disorders were also observed at lower rates.

The findings add to a growing body of evidence suggesting that the burden of CSU extends well beyond recurrent wheals and angioedema. Several studies included in the review demonstrated notable rates of psychiatric illness among patients with CSU, with some reports identifying psychiatric disorders in nearly half of affected individuals. Importantly, the literature also documented suicidal ideation in select patient cohorts, highlighting the need for clinicians to remain attentive to psychological symptoms during routine care.^2,3

The review points to neuroimmune dysregulation as a potential biological explanation for the relationship between CSU and psychiatric disease.¹ The authors describe a “neuro-immuno-cutaneous axis” connecting the skin, nervous system, and immune system. Chronic psychological stress may activate the hypothalamic-pituitary-adrenal axis and sympathetic nervous system, eventually leading to altered cortisol responses and increased production of pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha. These mediators are implicated in mast cell activation, a central feature of CSU pathogenesis.

Emerging research has also identified changes in brain regions involved in itch perception and emotional processing, including the anterior cingulate cortex, insula, and prefrontal cortex. Investigators have proposed that CSU may represent a neuroinflammatory disorder characterized by bidirectional communication among sensory neurons, mast cells, cytokines, and the central nervous system.

Beyond psychiatric diagnoses alone, the review emphasizes the significant effect of mental health symptoms on patient quality of life. Multiple studies demonstrated that anxiety, depression, stress, and somatoform symptoms were among the strongest predictors of impaired quality of life in CSU, often exerting a greater influence than demographic or disease-related factors. Disease severity was consistently associated with worse psychosocial outcomes.

Indian studies summarized in the review revealed similar trends. Reported rates of depression ranged from approximately 30% to more than 40%, while anxiety affected roughly one-third of patients. Investigators also found associations between psychological stress, inflammatory markers, sleep disturbance, and disease severity. However, the authors caution that most available data are derived from tertiary-care centers and may not fully represent the broader population.

From a clinical perspective, the review supports incorporating mental health screening into routine CSU management. Tools such as the Hospital Anxiety and Depression Scale, Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, and disease-specific quality-of-life instruments may help identify patients experiencing psychological distress.

The authors also discuss therapeutic strategies that extend beyond conventional antihistamine-based treatment. Psychological interventions, including cognitive behavioral therapy, mindfulness practices, and acceptance and commitment therapy, may help reduce stress-related disease exacerbations. Limited evidence from small studies and case reports suggests that selective serotonin reuptake inhibitors, tricyclic antidepressants, and trauma-focused psychotherapy may improve both psychiatric symptoms and urticaria outcomes in selected patients.

At the same time, advances in biologic and targeted therapies continue to expand treatment options for refractory disease. Agents such as omalizumab, dupilumab, and Janus kinase inhibitors may address both inflammatory and neuroimmune pathways implicated in CSU. Investigational approaches targeting neuropeptides, including substance P and calcitonin gene-related peptide, represent additional areas of interest.

Although the review highlights substantial progress in understanding the psychological dimensions of CSU, significant knowledge gaps remain. The authors call for larger, multicenter, population-based studies, particularly in India, to better define the prevalence of psychiatric comorbidities and guide culturally relevant psychodermatologic care.

For clinicians, the message is clear: effective CSU management may require addressing not only cutaneous symptoms but also the psychological factors that contribute to disease burden, treatment response, and overall patient well-being.

References

1. Kumaran MS, Kaur S, Narang T. Psychiatric comorbidities in chronic spontaneous urticaria: an overlooked dimension. Indian Dermatol Online J. 2026. doi:10.4103/idoj.idoj_339_25
2. Tzur Bitan D, Berzin D, Cohen A. The association of chronic spontaneous urticaria (CSU) with anxiety and depression: a nationwide cohort study. Arch Dermatol Res. 2021;313(1):33-39. doi:10.1007/s00403-020-02064-3
3. Sampogna F, Abeni D, Schut C, et al. Suicidal ideation in patients with skin conditions: A multicentre European study. J Eur Acad Dermatol Venereol. 2026. doi:10.1111/jdv.70523